1. Home
  2. ALTI vs CLLS Comparison

ALTI vs CLLS Comparison

Compare ALTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$4.15

Market Cap

394.0M

Sector

Finance

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.54

Market Cap

374.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTI
CLLS
Founded
2020
1999
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.0M
374.2M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ALTI
CLLS
Price
$4.15
$3.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
97.7K
32.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
41.11
N/A
EPS
N/A
N/A
Revenue
$206,935,000.00
N/A
Revenue This Year
$19.78
$40.37
Revenue Next Year
$7.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.33
$1.10
52 Week High
$5.45
$5.48

Technical Indicators

Market Signals
Indicator
ALTI
CLLS
Relative Strength Index (RSI) 38.31 39.15
Support Level $4.07 $3.41
Resistance Level $4.31 $3.77
Average True Range (ATR) 0.23 0.17
MACD -0.04 -0.02
Stochastic Oscillator 14.13 1.35

Price Performance

Historical Comparison
ALTI
CLLS

About ALTI AlTi Global Inc.

AlTi Global Inc is an independent wealth and asset manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. The firm has business which is organized into two business segments namely: Wealth & Capital Solutions and the International Real Estate segment includes providing holistic solutions for wealth management clients through comprehensive range of wealth management services, including investment management and advisory services. International Real Estate segment includes assist investors with real estate co-investments, structuring and selecting partners with a track record with risk adjusted return characteristics.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: